CN104119280A - Pyrimidine derivatives containing semicarbazide and terminal alkyne structural units, and preparation methods and applications of pyrimidine derivatives - Google Patents

Pyrimidine derivatives containing semicarbazide and terminal alkyne structural units, and preparation methods and applications of pyrimidine derivatives Download PDF

Info

Publication number
CN104119280A
CN104119280A CN201410295919.8A CN201410295919A CN104119280A CN 104119280 A CN104119280 A CN 104119280A CN 201410295919 A CN201410295919 A CN 201410295919A CN 104119280 A CN104119280 A CN 104119280A
Authority
CN
China
Prior art keywords
iii
preparation
general formula
amino
urea
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201410295919.8A
Other languages
Chinese (zh)
Other versions
CN104119280B (en
Inventor
刘宏民
马立英
王博
庞露苹
王志茹
张淼
户彪
郑甲信
马玉培
张笑丹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhengzhou University
Original Assignee
Zhengzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhengzhou University filed Critical Zhengzhou University
Priority to CN201410295919.8A priority Critical patent/CN104119280B/en
Publication of CN104119280A publication Critical patent/CN104119280A/en
Application granted granted Critical
Publication of CN104119280B publication Critical patent/CN104119280B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/38—One sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

The invention belongs to the field of medicinal chemistry, and discloses pyrimidine compounds containing semicarbazide and terminal alkyne structural units, and preparation methods and applications of the pyrimidine compounds in preparation of antitumor drugs by taking lysine specific demethylase 1 (hereafter referred to as LSD1) as a target. A pyrimidine active fragment is built by adopting a three-component one-pot method, and then the target compounds are prepared by substitution, chlorination and ammonification reaction. The general formulas of the compounds are as shown in the formula I in the specification. An in vitro anti-tumor activity experiment and an LSD1 inhibition activity experiment prove that the compounds have obvious inhibiting and killing action on a plurality of tumor cells by inhibiting the activity of the LSD1, can be used as lead compounds for further development, and are applied to preparation of the antitumor drugs.

Description

Pyrimidine derivatives, preparation method and application containing amino urea and Terminal Acetylenes structural unit
Technical field
The invention belongs to pharmaceutical chemistry field, be specifically related to a class containing Urea,amino-with the pyrimidine compound of Terminal Acetylenes structural unit, they preparation method and in preparation, take the application of istone lysine specificity demethylase (hereinafter to be referred as LSD1) in target antitumor drug.
Background technology
Tumour is serious harm human health and the disease that is difficult to overcome, and the antitumor drug having gone on the market at present also has a lot, but in these medicines, still has some problems, such as toxicity is large, a little less than targeting and easily produce resistance etc.Therefore, the research and development of new type antineoplastic medicine seem particularly important.
Covalent histone modifications is a kind of important epigenetic pattern, comprises acetylation of histone, methylates, phosphorylation and ubiquitination etc., and wherein acetylize is the histone modification mode for many in histone modification Mechanism Study with methylating.Histone methylatedly before 2004 be considered to forever irreversible, Methionin specificity histone demethylase (lysine specific demethylase 1, LSD1) be the 1st time found can catalysis histone H 3 K4 and the specificity demethylase of H3K9 demethylation, can remove the single, double of histone K4, K9 methylates, thereby regulate the interaction of histone and other albumen, and affect the Activation and inhibition of genetic transcription, the important vital process such as x chromosome inactivation.
LSD1 expression amount of LSD1 in kinds of tumor cells is significantly higher than normal cell, as neuroblastoma, cancer eye, prostate cancer, mammary cancer, lung cancer, bladder cancer etc.And experiment showed, that the activity that is reduced LSD1 expression amount or reduce LSD1 at cell levels by RNAi technology or micromolecular inhibitor can suppress cell proliferation and induce the expression of some cytodifferentiation genes involveds; Under the effect of small molecules oxidase inhibitor PCPA, also can suppress the growth of kinds of tumor cells and solid tumor.Therefore, LSD1 inhibitor can not only be used for setting forth biological function as the research tool of epigenetics, and can as epigenetics medicine, be used for prevention and the treatment of tumour, has caused the extensive concern of scientific research circle, becomes the focus of current research.
Meanwhile, also have report to confirm, pyrimidines has biological activity very widely, such as antiviral, antibacterial, anti-inflammatory and antitumor etc.But the report that pyrimidines and antitumor action based on LSD1 target spot is combined to research is less, so this research has very important value.
Summary of the invention
For developing existing clinical medicine resource, the object of the invention is to provide a class 2-(3,4-sulphur proyl)-4-replacement-5-cyano group-6-amino urea pyrimidine derivant, thus for finding the new antitumor drug based on LSD1 target spot of a class, open up a new way; Another object of the present invention is to provide its preparation method; Another object is to provide its application in preparing antitumor drug and LSD1 inhibitor.
The amino ureas pyrimidine derivatives of 2-of the present invention (3,4-sulphur proyl)-4-replacement-5-cyano group-6-general structure is as follows:
I
R in general formula I 1for Cl, , , in any one;
R 2for any one in following group:
、 、 、 、 、 、 、 、 、 、 。
Preferred:
R 1for Cl, in any one;
R 2for any one in following group:
、 、 、 、 、 、 、 、 、 、 、 。
Preferred:
R 1for ;
R 2for any one in following group:
、 、 、 、 、 、 、 。
Preferred:
R 1for ;
R 2for any one in following group:
， 。
More preferably one of following compound:
R 1during for Cl: III-1 R 2=Phenyl;
III-2 R 2=4-Chlorophenyl ；
III-3 R 2=3,4,5-Trimethoxylphenyl；
III-4 R 2=3,4-Difluorophenyl；
III-5 R 2=4-Bromophenyl；
III-6 R 2=4-Isoproplphenyl；
III-7 R 2=4-Fluorophenyl；
III-8 R 2=4-Methylphenyl；
III-9 R 2=4-Nitrophenyl；
III-10 R 2=3-Chlorophenyl；
III-11 R 2=2-Thienyl；
R 1for time: I-1 R 2=Phenyl;
I-2 R 2= 4-Chlorophenyl；
I-3 R 2= 3,4,5-Trimethoxylphenyl；
I-4 R 2= 3,4-Difluorophenyl；
I-5 R 2= 4-Bromophenyl；
I-6 R 2=4-Isoproplphenyl；
I-7 R 2= 4-Fluoropheny；
I-8 R 2=4-Methylphenyl；
I-9R 2= 4-Nitrophenyl；
I-10R 2=3-Chlorophenyl；
I-11R 2=3-Methoxylphenyl；
I-12 R 2=2-Thienyl；
R 1for time: I-13 R 2=3,4-Difluorophenyl;
I-14 R 2=4-Methylphenyl；
I-15 R 2=3-Chlorophenyl；
I-16 R 2= 4-Nitrophenyl；
I-17 R 2= 4-Bromophenyl；
I-18 R 2=4-Chlorophenyl；
I-19R 2=4-Isoproplphenyl；
R 1for time: I-20 R 2=4-Nitrophenyl.
The amino ureas pyrimidine derivatives of 2-of the present invention (3,4-sulphur proyl)-4-replacement-5-cyano group-6-, mainly makes by following steps:
(1) preparation method of general formula I I:
In solvent, by ethyl cyanacetate under alkaline condition and thiocarbamide, substituted benzoyl aldehyde reaction obtain Compound I I, alkali used is a kind of in sodium hydroxide, potassium hydroxide, sodium carbonate, salt of wormwood, sodium phosphate, ten phosphate dihydrate sodium, potassiumphosphate, saleratus, sodium bicarbonate, triethylamine; Solvent used is acetone, DMF, acetonitrile, ethanol, methyl alcohol, Virahol, 1, one of in 2-ethylene dichloride, methylene dichloride, chloroform, tetrahydrofuran (THF), dioxane, distilled water or wherein any two or three mixture; Reaction is carried out conventionally between 0-90 ℃.Products therefrom obtains sterling through suction filtration, recrystallization.Recrystallization solvent used is a kind of in ethanol, methyl alcohol, acetonitrile, acetone, ethyl acetate, tetrahydrofuran (THF), methylene dichloride, chloroform or the mixture of two kinds wherein.
Preferred temperature 25-60 ℃.
(2) preparation method of general formula III:
In solvent, general formula I I reacts and obtains intermediate product with propargyl bromide, with thin-layer chromatography, monitors reaction process, until reacted; Without separation, directly in reaction system, drip phosphorus oxychloride, after having reacted, be poured in frozen water, stir, there is solid to separate out, suction filtration, obtains solid, obtains the solid of sterling compound III through column chromatography.Solvent used is acetone, DMF, acetonitrile, ethanol, methyl alcohol, Virahol, 1, one of in 2-ethylene dichloride, methylene dichloride, chloroform, tetrahydrofuran (THF), dioxane, distilled water or wherein any two or three mixture; Reaction is carried out conventionally between 0-90 ℃.
Preferred temperature 25-60 ℃.
(3) preparation method of target compound I:
In solvent, compound corresponding in general formula III reacts with Urea,amino-compounds, after question response completes, separates out solid, and suction filtration obtains corresponding compound in general formula I.Solvent used is acetone, DMF, acetonitrile, ethanol, methyl alcohol, Virahol, 1, one of in 2-ethylene dichloride, methylene dichloride, chloroform, tetrahydrofuran (THF), dioxane, distilled water or wherein any two or three mixture; Reaction is carried out conventionally between 0-90 ℃.Products therefrom can obtain straight product through appropriate means as purifications such as column chromatography or recrystallizations.Crystallization solvent for use is a kind of in ethanol, methyl alcohol, acetonitrile, acetone, ethyl acetate, tetrahydrofuran (THF), methylene dichloride, chloroform or the mixture of two kinds wherein; In reaction amino ureas used be aminoguanidine, Urea,amino-, thiosemicarbazide.
Preferred temperature 25-60 ℃.
2-(3 of the present invention, 4-sulphur proyl) the amino ureas pyrimidine derivatives of-4-replacement-5-cyano group-6-has good restraining effect to stomach cancer cell (MGC-803, HGC-27, SGC-7901), liver cancer cell (HepG-2) and prostate cancer cell (PC-3), contrast with the antitumor drug 5 FU 5 fluorouracil having used clinically, be better than the latter.Meanwhile, by the experiment of LSD1 enzymic activity, find that LSD1 is also had to good restraining effect.Wherein the activity of compound is less than 2 μ M mostly, is better than positive control tranylcypromine (2-PCPA).Therefore, this type of 2-(3 provided by the invention, 4-sulphur proyl) drug combination and novel LSD1 inhibitor medicaments that the amino ureas pyrimidine derivatives of-4-replacement-5-cyano group-6-is development of new antitumor drug, medicine have been opened up another effective way, this compounds synthetic reasonable in design, reaction conditions is gentle, simple to operate, reaction yield is high, if exploitation becomes new drug, will have good market application foreground.
embodiment:
For the present invention is better illustrated, as follows especially exemplified by embodiment:
General formula ( iI) preparation with reference to making with Publication about Document:
H.I. Skulnick, J.H. Ludens, M.G. Wendling. Journal of Medicinal Chemistry, 1986, 29, 1499-1504.
embodiment 1general formula ( iI) shown in, R 2the derivative of=Phenyl ( iI-1) preparation
By ethyl cyanacetate (2.3g, 20mmol) with sodium hydroxide (1.2g, 30mmol) add in ethanolic soln, under reflux conditions, reaction for some time, then by thiocarbamide (2.3g, 30mmol) and phenyl aldehyde (3.2g, 30mmol) add in reaction system, stirring reaction, TLC follows the tracks of detection.After reaction finishes, suction filtration, recrystallization obtains sterling.Yield 92%, yellow solid.
embodiment 2general formula ( iII) shown in, R 1=Cl, R 2the derivative of=Phenyl ( iII-1) preparation
Propargyl bromide (3.6g, 30mmol) is dropwise added in Isosorbide-5-Nitrae-dioxane solution of II-1 (2.7g, 10mmol) to 60 ℃ of heated and stirred reactions.With TLC, monitor reaction process, until reacted; Without separation, directly in reaction system, drip phosphorus oxychloride (4.6g, 30mmol), after having reacted, be poured in frozen water, stir, there is solid to separate out, suction filtration, obtains solid, obtains the solid of sterling compound III-1 through column chromatography.Productive rate 64%, faint yellow solid.Fusing point: 131-132 oc. 1H NMR (400 MHz, CDCl 3, δ, ppm) δ 8.20 – 8.07 (m, 2H, Ar-H), 7.70 – 7.52 (m, 3H, Ar-H), 4.01 (d, J = 2.6 Hz, 2H, -CH 2-), 2.28 (t, J = 2.6 Hz, 1H, ≡C-H). 13C NMR (100 MHz, CDCl 3, δ, ppm): δ 174.02, 168.73, 163.95, 134.07, 132.72, 129.35, 129.02, 114.43, 101.42, 78.17, 71.63, 20.36. HR-MS (ESI): Calcd. C 14H 9ClN 3S, [M+H] +m/z: 286.0206, found: 286.0202.
embodiment 3general formula ( iII) shown in, R 1=Cl, R 2the derivative of=4-Chlorophenyl ( iII-2) preparation
Take the same method preparation of embodiment 1 iI-2, R 2=4-Chlorophenyl; Take the same method preparation of embodiment 2 iII-2, R 1=Cl, R 2=4-Chlorophenyl; 80 ° of C. of Mp:79 – 1h NMR (400 MHz, CDCl 3, δ, ppm) and δ 8.17 – 8.01 (m, 2H, Ar-H), 7.63 – 7.47 (m, 2H, Ar-H), 4.00 (d, j=2.6 Hz, 2H ,-CH 2-), 2.28 (t, j=2.6 Hz, 1H, ≡ C-H). 13c NMR (100 MHz, CDCl 3, δ, ppm): δ 174.20,167.41,164.04,139.39,132.39,130.69,129.40,114.27,101.19,78.07,71.66,20.40. HR-MS (ESI): Calcd. C 14h 8cl 2n 3s, [M+H] +m/z:319.9816, found:319.9818.
embodiment 4general formula ( iII) shown in, R 1=Cl, R 2=3, the derivative of 4,5-Trimethoxylphenyl ( iII-3) preparation
Take the same method preparation of embodiment 1 iI-3, R 2=3,4,5-Trimethoxylphenyl; Take the same method preparation of embodiment 2 iII-3, R 1=Cl, R 2=3,4,5-Trimethoxylphenyl; 105 ° of C. of Mp:104 – 1h NMR (400 MHz, CDCl 3, δ, ppm) and δ 7.50 (s, 2H, Ar-H), 3.98 (d, j=2.7 Hz, 2H ,-CH 2-), 3.97 (s, 9H ,-CH 3), 2.26 (t, j=2.6 Hz, 1H, ≡ C-H). 13c NMR (100 MHz, CDCl 3, δ, ppm): δ 173.60,167.69,164.07,153.33,142.24,128.70,114.87,106.98,100.65,78.72,71.22,61.08,56.43,20.35. HR-MS (ESI): Calcd. C 17h 15clN 3o 3s, [M+H] +m/z:376.0523, found:376.0517.
embodiment 5general formula ( iII) shown in, R 1=Cl, R 2the derivative of=3,4-Difluorophenyl ( iII-4) preparation
Take the same method preparation of embodiment 1 iI-4, R 2=3,4-Difluorophenyl; Take the same method preparation of embodiment 2 iII-4, R 1=Cl, R 2=3,4-Difluorophenyl; 79 ° of C. of Mp:78 – 1h NMR (400 MHz, CDCl 3, δ, ppm) and δ 8.15 – 7.90 (m, 2H, Ar-H), 7.56 – 7.30 (m, 1H, Ar-H), 3.99 (t, j=3.7 Hz, 2H ,-CH 2-), 2.29 (t, j=2.6 Hz, 1H, ≡ C-H). 13c NMR (100 MHz, CDCl 3, δ, ppm): δ 174.35,166.08,164.16,130.83,126.20,119.11,118.90,118.20,118.02,114.10,101.15,78.07,71.70,20.44. HR-MS (ESI): Calcd. C 14h 7clF 2n 3s, [M+H] +m/z:322.0017, found:322.0013.
embodiment 6general formula ( iII) shown in, R 1=Cl, R 2the derivative of=4-Bromophenyl ( iII-5) preparation
Take the same method preparation of embodiment 1 iI-5, R 2=4-Bromophenyl; Take the same method preparation of embodiment 2 iII-5, R 1=Cl, R 2=4-Bromophenyl; 138 ° of C. of Mp:137 – 1h NMR (400 MHz, CDCl 3, δ, ppm) and δ 8.08 – 7.96 (m, 2H, Ar-H), 7.84 – 7.60 (m, 2H, Ar-H), 4.00 (d, j=2.6 Hz, 2H ,-CH 2-), 2.27 (t, j=2.6 Hz, 1H, ≡ C-H). 13c NMR (100 MHz, CDCl 3, δ, ppm): δ 174.24,167.54,164.06,132.85,132.39,130.78,127.98,114.24,101.19,78.09,71.65,20.40. HR-MS (ESI): Calcd. C 14h 8brClN 3s, [M+H] +m/z:363.9311, found:363.9314.
embodiment 7general formula ( iII) shown in, R 1=Cl, R 2the derivative of=4-Isoproplphenyl ( iII-6) preparation
Take the same method preparation of embodiment 1 iI-6, R 2=4-Isoproplphenyl; Take the same method preparation of embodiment 2 iII-6, R 1=Cl, R 2=4-Isoproplphenyl; 110 ° of C. of Mp:109 – 1h NMR (400 MHz, CDCl 3, δ, ppm) and δ 8.15 – 8.00 (m, 2H, Ar-H), 7.44 (m, 2H, Ar-H), 4.01 (d, j=2.6 Hz, 2H ,-CH 2-), 3.03 (hept, j=6.9 Hz, 1H, CH), 2.28 (t, j=2.6 Hz, 1H, ≡ C-H), 1.33 (d, j=6.9 Hz, 6H ,-CH 3). 13c NMR (100 MHz, CDCl 3, δ, ppm): δ 173.81,168.55,163.92,131.62,129.53,127.21,114.66,100.97,84.40,78.06,71.57,34.29,23.66,20.31. HR-MS (ESI): Calcd. C 17h 15clN 3s, [M+H] +m/z:328.0675, found:328.0677.
embodiment 8general formula ( iII) shown in, R 1=Cl, R 2the derivative of=4-Fluorophenyl ( iII-7) preparation
Take the same method preparation of embodiment 1 iI-7, R 2=4-Fluorophenyl; Take the same method preparation of embodiment 2 iII-7, R 1=Cl, R 2=4-Fluorophenyl; 97 ° of C. of Mp:96 – 1h NMR (400 MHz, CDCl 3, δ, ppm) and δ 8.23 – 8.12 (m, 2H, Ar-H), 7.35 – 7.19 (m, 2H, Ar-H), 4.00 (d, j=2.6 Hz, 2H ,-CH 2-), 2.28 (t, j=2.6 Hz, 1H, ≡ C-H). 13c NMR (100 MHz, CDCl 3, δ, ppm): δ 174.07,167.36,164.02,131.84,130.17,116.25,114.41,101.04,84.21,78.14,71.63,20.37. HR-MS (ESI): Calcd. C 14h 8clFN 3s, [M+H] +m/z:304.0111, found:304.0114.
embodiment 9general formula ( iII) shown in, R 1=Cl, R 2the derivative of=4-Methylphenyl ( iII-8) preparation
Take the same method preparation of embodiment 1 iI-8, R 2=4-Methylphenyl; Take the same method preparation of embodiment 2 iII-8, R 1=Cl, R 2=4-Methylphenyl; 122 ° of C. of Mp:121 – 1h NMR (400 MHz, CDCl 3, δ, ppm) δ 8.05 (d, j=8.2 Hz, 2H, Ar-H), 7.39 (d, j=8.1 Hz, 2H, Ar-H), 4.01 (d, j=2.6 Hz, 2H ,-CH 2-), 2.28 (t, j=2.6 Hz, 1H, ≡ C-H). 13c NMR (100 MHz, CDCl 3, δ, ppm): δ 173.79,168.53,163.91,143.76,131.30,129.76,114.64,100.96,84.11,78.30,71.57,21.69,20.32. HR-MS (ESI): Calcd. C 15h 11clN 3s, [M+H] +m/z:300.0362, found:300.0363.
embodiment 10general formula ( iII) shown in, R 1=Cl, R 2the derivative of=4-Nitrophenyl ( iII-9) preparation
Take the same method preparation of embodiment 1 iI-9, R 2=4-Nitrophenyl; Take the same method preparation of embodiment 2 iII-9, R 1=Cl, R 2=4-Nitrophenyl; 102 ° of C. of Mp:101 – 1h NMR (400 MHz, CDCl 3) δ 8.43 (d, j=8.9 Hz, 2H, Ar-H), 8.28 (d, j=8.9 Hz, 2H, Ar-H), 4.01 (d, j=2.6 Hz, 2H ,-CH 2-), 2.29 (t, j=2.6 Hz, 1H, ≡ C-H). 13c NMR (100 MHz, CDCl 3, δ, ppm): δ 8.45,8.42,8.30,8.27,4.01,4.00,2.30,2.29,2.29.HR-MS (ESI): Calcd. C 14h 8clN 4o 2s, [M+H] +m/z:331.0056, found:331.0056.
embodiment 11general formula ( iII) shown in, R 1=Cl, R 2the derivative of=3-Chlorophenyl ( iII-10) preparation
Take the same method preparation of embodiment 1 iI-10, R 2=3-Chlorophenyl; Take the same method preparation of embodiment 2 iII-10, R 1=Cl, R 2=3-Chlorophenyl; 137 ° of C. of Mp:136 – 1h NMR (400 MHz, CDCl 3, δ, ppm) and δ 8.17 – 8.01 (m, 2H, Ar-H), 7.63 – 7.47 (m, 2H, Ar-H), 4.00 (d, j=2.6 Hz, 2H ,-CH 2-), 2.28 (t, j=2.6 Hz, 1H, ≡ C-H). 13c NMR (100 MHz, CDCl 3, δ, ppm): δ 174.20,167.41,164.04,139.39,132.39,130.69,129.40,114.27,101.19,78.07,71.66,20.40. HR-MS (ESI): Calcd. C 14h 8cl 2n 3s, [M+H] +m/z:319.9816, found:319.9818.
embodiment 12general formula ( iII) shown in, R 1=Cl, R 2the derivative of=2-Thenyl ( iII-11) preparation
Take the same method preparation of embodiment 1 iI-11, R 2=2-Thenyl; Take the same method preparation of embodiment 2 iII-11, R 1=Cl, R 2=2-Thenyl; 120 ° of C. of Mp:119 – 1h NMR (400 MHz, CDCl 3, δ, ppm) δ 8.52 (dd, j=4.0,0.9 Hz, 1H, Ar-H), 7.78 (dd, j=5.0,0.9 Hz, 1H, Ar-H), 7.27 (dd, j=4.9,4.1 Hz, 1H, Ar-H), 3.99 (d, j=2.6 Hz, 2H ,-CH 2-), 2.26 (t, j=2.6 Hz, 1H, ≡ C-H). 13c NMR (100 MHz, CDCl 3, δ, ppm): δ 8.45,8.42,8.30,8.27,4.01,4.00,2.30,2.29,2.29. HR-MS (ESI): Calcd. C 12h 7clN 3s 2, [M+H] +m/z:291.9770, found:291.9771.
embodiment 13general formula ( i) shown in, R 1= , R 2the derivative of=Phenyl ( i-1)preparation
Will iII-1(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml ethanol, after dissolving, adds thiosemicarbazide (223mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-1, with ethyl alcohol recrystallization, obtain i-1sterling.Yield 87%, yellow solid.Fusing point: 213-214 oc. 1H NMR (400 MHz, DMSO-d6, δ, ppm) δ 10.21 (s, 1H, pyrimidine-NH, D 2O exchangeable), 9.57 (s, 1H, thiourea-NH, D 2O exchangeable), 7.95 (d, J = 11.0 Hz, 1H, thiourea-NH 2, D 2O exchangeable), 7.91 (d, J = 6.0 Hz, 2H, Ar-H), 7.77 (s, 1H, thiourea-NH 2, D 2O exchangeable), 7.61 (t, J = 7.4 Hz, 3H, Ar-H).4.04 (s, 2H, -CH 2-), 3.20 (s, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d6, δ, ppm): δ182.71, 172.32, 167.56, 162.94, 136.04, 131.83, 129.18, 129.12, 115.60, 84.37, 80.25, 74.21, 19.63;HRMS (ESI) calcd for C 15H 13N 6S 2 [M+H] +:341.0643, found: 341.0641.
embodiment 14general formula ( i) shown in, R 1= , R 2the derivative of=4-Chlorophenyl ( i-2)preparation
Will iII-2(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml chloroform, after dissolving, adds thiocarbamide (169mg, 2mmol) under amino heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-2, with ethyl alcohol recrystallization, obtain i-2sterling.Yield 88%, yellow solid.Fusing point: 191-192 oc. 1H NMR (400 MHz, DMSO-d6 , δ , ppm)δ10.25 (s, 1H, pyrimidine-NH, D2O exchangeable), 9.58 (s, 1H, thiourea-NH, D2O exchangeable), 8.15–7.71 (m, 4H, Ar-H), 7.68 (d, J = 8.5 Hz, 2H, thiourea-NH2, D2O exchangeable), 4.03 (d, J = 2.5 Hz, 2H, -CH2-), 3.19 (t, J = 2.6 Hz, 1H, ≡C-H). 13C NMR (101 MHz, DMSO-d6)δ182.62，172.32，166.31，162.69，136.77，134.79，131.04，129.29，115.45，84.07，80.17，74.27，19.64;HRMS (ESI) calcd for C 15H 12ClN 6O 5S 2 [M+H] +: 375.0253, found: 375.0256.
embodiment 15general formula ( i) shown in, R 1= , R 2=3, the derivative of 4,5-Trimethoxylphenyl ( i-3)preparation
Will iII-3(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml acetone, after dissolving, adds thiosemicarbazide (100mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-3, with ethyl alcohol recrystallization, obtain i-3sterling.Yield 85.7%, yellow solid.Fusing point: 196-197 oc. 1H NMR (400 MHz, DMSO-d6, δ, ppm) δ 10.15 (s, 1H, pyrimidine-NH, D 2O exchangeable), 9.57 (s, 1H, thiourea-NH, D 2O exchangeable), 7.95 (s, 1H, thiourea-NH 2, D 2O exchangeable), 7.75 (s, 1H, thiourea-NH 2, D 2O exchangeable), 7.31 (s, 2H, Ar-H), 4.02 (d, J = 2.3 Hz, 2H, -CH 2-), 3.86 (s, 6H, -OCH 3), 3.78 (s, 3H, -OCH 3), 3.22 (t, J = 2.5 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d6, δ, ppm): δ 182.63, 172.11, 166.67, 163.11, 153.17, 140.63, 131.00, 115.88, 106.97, 83.94, 80.74, 73.76, 60.69, 56.58, 19.77;HRMS (ESI) calcd for C 18H 18N 6NaO 3S 2 [M+Na] +: 453.0779, found: 453.0779.
embodiment 16general formula ( i) shown in, R 1= , R 2the derivative of=3,4-Difluorophenyl ( i-4)preparation
Will iII-4(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml tetrahydrofuran (THF), after dissolving, adds thiosemicarbazide (202mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-4, with ethyl alcohol recrystallization, obtain i-4sterling.Yield 85.7%, yellow solid.Fusing point: 186-187 oc. 1H NMR (400 MHz, DMSO-d 6 ,δ , ppm) δ 10.28 (s, 1H, pyrimidine-NH, D 2O exchangeable), 9.60 (s, 1H, thiourea-NH, D 2O exchangeable), 7.97 (s, 2H, thiourea-NH 2, D 2O exchangeable), 7.87 – 7.60 (m, 3H, Ar-H), 4.04 (d, J = 2.5 Hz, 2H, -CH 2-), 3.21 (t, J = 2.6 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d6, δ, ppm): δ182.63, 172.47, 165.02, 162.85, 153.09, 148.60, 141.22, 133.43, 126.68, 118.61, 115.35, 84.67, 80.25, 74.22, 19.69;HRMS (ESI) calcd for C 15H 10F 2N 6NaS 2 [M+Na] +: 399.0274, found: 399.0276.
embodiment 17general formula ( i) shown in, R 1= , R 2the derivative of=4-Bromophenyl ( i-5)preparation
Will iII-5(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml methylene dichloride, after dissolving, adds thiosemicarbazide (181mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-5, with ethyl alcohol recrystallization, obtain i-5sterling.Yield 85%, yellow solid.Fusing point: 185-186 oc. 1H NMR (400 MHz, DMSO-d 6 ,δ , ppm) δ 10.26 (s, 1H, pyrimidine-NH, D 2O exchangeable), 9.58 (s, 1H, thiourea-NH, D 2O exchangeable), 8.64 (s, 2H, thiourea-NH 2, D 2O exchangeable), 8.01 – 7.47 (m, 4H, Ar-H), 4.03 (d, J = 2.5 Hz, 2H, -CH 2-), 3.19 (t, J = 2.6 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d6, δ, ppm): δ 181.73, 172.33, 166.99, 162.69, 135.16, 132.22, 131.19, 125.66, 115.46, 84.09, 80.18, 74.26, 19.64;HRMS (ESI) calcd for C 15H 11B rN 6NaS 2 [M+Na] +: 440.9568, found: 440.9567.
embodiment 18general formula ( i) shown in, R 1= , R 2the derivative of=4-Isoproplphenyl ( i-6)preparation
Will iII-6(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml dioxy six alkane, after dissolving, adds thiosemicarbazide (202mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-6, with ethyl alcohol recrystallization, obtain i-6sterling.Yield 85.7%, yellow solid.Fusing point: 191 – 192 oc. 1H NMR (400 MHz, DMSO-d 6, δ, ppm)δ10.15 (s, 1H, pyrimidine-NH, D 2O exchangeable), 9.53 (s, 1H, thiourea-NH, D 2O exchangeable), 7.96 (s, 1H, thiourea-NH 2, D 2O exchangeable), 7.87 (d, J = 7.9 Hz, 2H, Ar-H), 7.75 (s, 1H, thiourea-NH 2, D 2O exchangeable), 7.47 (d, J = 8.1 Hz, 2H, Ar-H), 4.03 (d, J = 2.4 Hz, 2H, -CH 2-), 3.19 (t, J = 2.5 Hz, 1H, ≡C-H), 3.00 (dt, J = 13.9, 6.9 Hz, 1H, CH), 1.27 (d, J = 6.9 Hz, 6H, CH 3). 13C NMR (100 MHz, DMSO-d6, δ, ppm): δ 188.67, 176.31, 169.69, 161.63, 137.70, 133.70, 129.33, 127.10, 115.71, 85.74, 80.31, 74.16, 33.90, 24.07, 19.59;HRMS (ESI) calcd for C 18H 19N 6S 2 [M+H] +: 383.1113, found: 383.1117.
embodiment 19general formula ( i) shown in, R 1= , R 2the derivative of=4-Fluoropheny ( i-7)preparation
Will iII-7(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml ethanol, after dissolving, adds thiosemicarbazide (212mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-7, with ethyl alcohol recrystallization, obtain i-7sterling.Yield 84.2%, faint yellow solid.Fusing point: 198-199 oc. 1H NMR (400 MHz, DMSO-d6, δ, ppm) δ 10.23 (s, 1H, pyrimidine-NH, D2O exchangeable), 9.58 (s, 1H, thiourea-NH, D2O exchangeable),8.01 (s, 1H, thiourea-NH2, D2O exchangeable), 7.98 (d, J = 5.5 Hz, 2H, Ar-H), 7.75 (s, 1H, thiourea-NH, D2O exchangeable2), 7.44 (t, J = 8.8 Hz, 2H, Ar-H), 4.03 (d, J = 2.5 Hz, 2H, -CH2-), 3.19 (t, J = 2.6 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d6, δ, ppm): δ 182.66, 172.30, 165.57, 163.09, 132.48, 131.77, 116.37, 115.58, 112.98, 84.20, 80.23, 74.22, 19.63;HRMS (ESI) calcd for C 15H 12FN 6S 2 [M+H] +: 359.0549, found: 359.0551.
embodiment 20general formula ( i) shown in, R 1= , R 2the derivative of=4-Methylphenyl ( i-8)preparation
Will iII-8(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml DMF, after dissolving, adds thiocarbamide (215mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-8, with ethyl alcohol recrystallization, obtain i-8sterling.Yield 86%, yellow solid.Fusing point: 178 – 179 oc. 1H NMR (400 MHz, DMSO-d6, δ, ppm) δ 10.13 (s, 1H, pyrimidine-NH, D 2O exchangeable), 9.52 (s, 1H, thiourea-NH, D 2O exchangeable), 7.92 (s, 1H, thiourea-NH 2, D 2O exchangeable), 7.80 (d, J = 7.8 Hz, 2H, Ar-H), 7.73 (s, 1H, thiourea-NH 2, D 2O exchangeable), 7.37 (d, J = 8.0 Hz, 2H, Ar-H), 4.00 (d, J = 2.5 Hz, 2H, -CH 2-), 3.16 (t, J = 2.6 Hz, 1H, ≡C-H), 2.39 (s, 3H). 13C NMR (100 MHz, DMSO-d6, δ, ppm): δ 182.71, 175.33, 172.16, 163.06, 142.04, 133.23, 129.68, 129.18, 115.73, 83.93, 80.28, 74.18, 21.52, 19.60;HRMS (ESI) calcd for C 16H 15N 6S 2 [M+H] +: 355.0800, found: 355.0803.
embodiment 21general formula ( i) shown in, R 1= , R 2the derivative of=4-Nitrophenyl ( i-9)preparation
Will iII-9(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml acetonitrile, after dissolving, adds thiosemicarbazide (198mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-9, with ethyl alcohol recrystallization, obtain i-9sterling.Yield 84%, yellow solid.Mp: 152–153°C. 1H NMR (400 MHz, DMSO-d 6, δ, ppm) δ 10.38 (s, 1H, pyrimidine-NH, D 2O exchangeable), 9.65 (s, 1H, thiourea-NH, D 2O exchangeable), 8.43 (d, J = 8.4 Hz, 2H, Ar-H), 8.13 (d, J = 7.0 Hz, 2H, Ar-H), 8.01 (s, 1H, thiourea-NH 2, D 2O exchangeable), 7.76 (s, 1H, thiourea-NH 2, D 2O exchangeable), 4.04 (s, 2H, -CH 2-), 3.22 (s, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d 6, δ, ppm): δ 180.60, 172.70, 168.33, 165.85, 149.41, 141.86, 130.69, 124.27, 115.04, 85.22, 80.06, 74.35, 19.70. HR-MS (ESI): Calcd. C 15H 12N 7O 2S 2, [M+H] +m/z: 386.0494, found: 386.0497.
embodiment 22general formula ( i) shown in, R 1= , R 2the derivative of=3-Chlorophenyl ( i-10)preparation
Will iII-10(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml distilled water, after dissolving, adds thiosemicarbazide (200mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-10, with ethyl alcohol recrystallization, obtain i-10sterling.Yield 79%, yellow solid.Fusing point: 178-179 oc. 1H NMR (400 MHz, DMSO-d6 , δ , ppm)δ10.25 (s, 1H, pyrimidine-NH, D2O exchangeable), 9.58 (s, 1H, thiourea-NH, D2O exchangeable), 8.15–7.71 (m, 4H, Ar-H), 7.68 (d, J = 8.5 Hz, 2H, thiourea-NH2, D2O exchangeable), 4.03 (d, J = 2.5 Hz, 2H, -CH2-), 3.19 (t, J = 2.6 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d6)δ 182.62，172.32，166.31，162.69，136.77，134.79，131.04，129.29，115.45，84.07，80.17，74.27，19.64;HRMS (ESI) calcd for C 15H 12ClN 6O 5S 2 [M+H] +: 375.0253, found: 375.0256.
embodiment 23general formula ( i) shown in, R 1= , R 2the derivative of=3-Methoxylphenyl ( i-11)preparation
Take the same method preparation of embodiment 1 iI-11, R 2=3-Methoxylphenyl; Take the same method preparation of embodiment 2 iII-11, R 1=Cl, R 2=3-Methoxylphenyl;
Will iII-11(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml ethanol, after dissolving, adds thiosemicarbazide (210mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-11, with ethyl alcohol recrystallization, obtain i-11sterling.Yield 82%, yellow solid.Fusing point: 163-164 oc.
embodiment 24general formula ( i) shown in, R 1= , R 2=2-Thienyl derivative ( i-12)preparation
Will iII-12(500mg, 1mmol) adds in 50ml round-bottomed flask, adds 20ml methyl alcohol, after dissolving, adds thiosemicarbazide (230mg, 2mmol) under heated and stirred, heating reflux reaction, TLC tracking monitor.After question response completes, condensation, separates out solid, and suction filtration obtains compound i-12, with ethyl alcohol recrystallization, obtain i-12sterling.Yield 82%, yellow solid.Mp: 204–205°C. 1H NMR (400 MHz, DMSO-d 6, δ, ppm) δ 10.20 (s, 1H, NH, D 2O exchangeable), 9.53 (s, 1H, NH, D 2O exchangeable), 8.26 (d, J = 2.7 Hz, 1H, Ar-H), 8.01 (d, J = 4.4 Hz, 1H, Ar-H), 7.95 (s, 1H, NH, D 2O exchangeable), 7.76 (s, 1H, NH, D 2O exchangeable), 7.42 – 7.24 (m, 1H, Ar-H), 4.02 (d, J = 2.5 Hz, 2H, -CH 2-), 3.17 (t, J = 2.6 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d 6, δ, ppm): δ 182.64, 172.00, 163.11, 158.83, 140.12, 134.20, 131.39, 129.62, 115.93, 80.13, 74.13, 19.61. HR-MS (ESI): Calcd. C 13H 11N 6S 3, [M+H] +m/z: 347.0207, found: 347.0210.
embodiment 25general formula ( i) shown in, R 1= , R 2the derivative of=3,4-Difluorophenyl ( i-13)preparation
Prepare iII-4,take the same method of embodiment 16 that thiosemicarbazide is replaced with to Urea,amino-, preparation i-13.
Fusing point: 186-187 oc. 1H NMR (400 MHz, DMSO-d 6, δ, ppm) δ 9.94 (s, 1H, pyrimidine-NH, D 2O exchangeable), 8.14 (s, 1H, urea-NH, D 2O exchangeable), 8.03 – 7.63 (m, 3H, Ar-H), 6.14 (s, 2H, urea-NH 2, D 2O exchangeable), 4.02 (d, J = 2.4 Hz, 2H, -CH 2-), 3.21 (t, J = 2.5 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d 6) δ 179.64, 175.66, 172.63, 163.32, 148.70, 133.71, 126.78, 123.15, 118.84, 118.35, 115.72, 83.70, 80.26, 74.18, 19.58;HRMS (ESI) calcd for C 15H 10F 2N 6N aOS[M+N a] +: 383.0503, found: 383.0504.
embodiment 26general formula ( i) shown in, R 1= , the derivative of 4-Methylphenyl ( i-14)preparation
Prepare iII-8,take the same method of embodiment 20 that thiosemicarbazide is replaced with to Urea,amino-, preparation i-14.fusing point: 193-194 oc. 1H NMR (400 MHz, DMSO-d 6, δ, ppm) δ 9.96 (s, 1H, pyrimidine-NH, D 2O exchangeable), 8.22 (s, 1H, urea-NH, D 2O exchangeable), 7.67 (m, 4H, Ar-H), 6.20 (d, J = 47.3 Hz, 2H, urea-NH 2, D 2O exchangeable), 4.08 (d, J = 54.9 Hz, 2H, -CH 2-), 3.33 (s, 1H, ≡C-H), 2.51 (s, 1H, -CH 3). 13C NMR (100 MHz, DMSO-d 6) δ 186.63, 172.33, 167.66, 163.67, 141.68, 129.59, 129.23, 115.99, 109.68, 86.04, 80.38, 74.13, 21.51, 19.48;HRMS (ESI) calcd for C 16H 14N 6N aS[M+N a] +: 361.0847, found: 361.0845.
embodiment 27general formula ( i) shown in, R 1= , R 2the derivative of=3-Chlorophenyl ( i-15)preparation
Prepare iII-10,take the same method of embodiment 22 that thiosemicarbazide is replaced with to Urea,amino-, preparation i-15.yield 86%, yellow solid.Fusing point: 187-188 oc. 1H NMR (400 MHz, DMSO-d 6, δ, ppm) δ 9.91 (s, 1H, pyrimidine-NH, D 2O exchangeable), 8.11 (s, 1H, urea-NH, D 2O exchangeable), 7.93 – 7.53 (m, 4H, Ar-H), 6.12 (s, 2H, urea-NH 2, D 2O exchangeable), 3.99 (d, J = 2.5 Hz, 2H, -CH 2-), 3.18 (t, J = 2.5 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d 6) δ 186.02, 176.32, 166.01, 163.38, 138.08, 133.77, 131.52, 131.02, 128.96, 127.89, 115.45, 83.41, 80.27, 74.18, 19.56;HRMS (ESI) calcd for C 15H 11ClN 6N aOS[M+N a] +: 381.0301, found: 381.0301.
embodiment 28general formula ( i) shown in, R 1= , R 2the derivative of=4-Nitrophenyl ( i-16)preparation
Prepare iII-9,take the same method of embodiment 21 that thiosemicarbazide is replaced with to Urea,amino-, preparation i-16.yield 85.3%, yellow solid.Fusing point: 193-194 oc. 1H NMR (400 MHz, DMSO-d 6, δ, ppm) δ 10.03 (s, 1H, pyrimidine-NH, D 2O exchangeable), 8.42 (s, 1H, urea-NH, D 2O exchangeable), 8.40 (s, 1H, Ar-H), 8.15 (s, 3H, Ar-H), 6.16 (s, 2H, urea-NH 2, D 2O exchangeable), 4.03 (d, J = 2.3 Hz, 2H, -CH 2-), 3.20 (t, J = 2.6 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d 6) δ 172.69, 165.70, 163.22, 159.16, 149.35, 141.96, 130.75, 124.19, 115.21, 84.38, 80.05, 74.32, 19.59;HRMS (ESI) calcd for C 15H 12N 7O 3S[M+H] +: 370.0722, found: 370.0723.
embodiment 29general formula ( i) shown in, R 1= , R 2the derivative of=4-Bromophenyl ( i-17)preparation
Prepare iII-5,take the same method of embodiment 17 that thiosemicarbazide is replaced with to Urea,amino-, preparation i-17.fusing point: 178-179 oc. 1H NMR (400 MHz, DMSO-d6, δ, ppm) δ 9.92 (s, 1H, pyrimidine-NH, D 2O exchangeable), 8.13 (s, 1H, urea-NH, D 2O exchangeable), 7.82 (m, 4H, Ar-H), 6.15 (s, 2H, urea-NH 2, D 2O exchangeable), 4.02 (d, J = 2.4 Hz, 2H, -CH 2-), 3.19 (t, J = 2.5 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d6, δ, ppm): δ 187.68, 179.33, 169.31, 163.44, 135.25, 132.14, 131.26, 125.59, 115.58, 83.40, 80.21, 74.22, 19.50;HRMS (ESI) calcd for C 15H 11B rN 6N aOS[M+N a] +: 424.9796, found: 424.9798.
embodiment 30general formula ( i) shown in, R 1= , R 2the derivative of=4-Chlorophenyl ( i-18)preparation
Prepare iII-2,take the same method of embodiment 14 that thiosemicarbazide is replaced with to Urea,amino-, preparation i-18.fusing point: 159 160 ° of – C. 1H NMR (400 MHz, DMSO-d6, δ, ppm) δ 10.25 (s, 1H, pyrimidine-NH, D 2O exchangeable), 9.58 (s, 1H, urea-NH, D 2O exchangeable), 7.95 (s, 1H, urea-NH 2, D 2O exchangeable), 7.93 (d, J = 8.1 Hz, 2H, Ar-H)，7.74 (s, 1H, urea-NH 2, D 2O exchangeable), 7.68 (d, J = 8.5 Hz, 2H, Ar-H), 4.03 (d, J = 2.5 Hz, 2H, -CH 2-), 3.19 (t, J = 2.6 Hz, 1H, ≡C-H). 13C NMR (100 MHz, DMSO-d6, δ, ppm): δ 182.68, 172.40, 166.67, 162.87, 136.78, 134.80, 131.04, 129.29, 115.45, 84.39, 80.17, 74.27, 19.64;HRMS (ESI) calcd for C 15H 12N 8O 2S[M+H] +: 368.0804, found: 368.0806.
embodiment 31general formula ( i) shown in, R 1= , R 2the derivative of=4-Isoproplphenyl ( i-19)preparation
Prepare iII-6,take the same method of embodiment 18 that thiosemicarbazide is replaced with to Urea,amino-, preparation i-18.Mp: 178–179°C. 1H NMR (400 MHz, DMSO-d 6, δ, ppm) δ 9.84 (s, 1H, pyrimidine-NH, D 2O exchangeable), 8.11 (s, 1H, thiourea-NH, D 2O exchangeable), 7.85 (s, 2H, Ar-H), 7.45 (d, J = 7.8 Hz, 2H, Ar-H), 6.16 (s, 2H, thiourea-NH 2, D 2O exchangeable), 4.01 (d, J = 2.4 Hz, 2H, -CH 2-), 3.20 (t, J = 2.5 Hz, 1H), 2.99 (dt, J = 13.7, 6.8 Hz, 1H, ≡C-H), 1.26 (d, J = 6.9 Hz, 6H). 13C NMR (100 MHz, DMSO-d 6, δ, ppm): δ 172.28, 167.48, 159.10, 152.51, 133.74, 129.36, 127.00, 115.99, 82.99, 80.37, 74.09, 33.90, 24.07, 19.46. HR-MS (ESI): Calcd. C 18H 19N 6OS, [M+H] +m/z: 367.1341, found: 367.1343.
embodiment 32general formula ( i) shown in, R 1= , R 2the derivative of=4-Nitrophenyl ( i-20)preparation
Prepare iII-9,take the same method of embodiment 21 that thiosemicarbazide is replaced with to Urea,amino-, preparation i-20.fusing point: 193-194 oc. 1H NMR (400 MHz, DMSO-d6, δ, ppm) δ 12.82 (s, 1H, NH, D 2O exchangeable), 8.64 – 8.27 (m, 2H, Ar-H), 8.12 (m, 2H, Ar-H), 5.25 (s, 2H, guanidine-NH 2, D 2O exchangeable), 4.05 (d, J = 2.5 Hz, 2H, -CH 2-), 3.16 (t, J = 2.5 Hz, 1H, ≡C-H) . 13C NMR (100 MHz, DMSO-d6, δ, ppm): δ 186.63, 174.36, 166.47, 161.34, 149.05, 142.73, 131.18, 124.27, 115.70, 84.09, 80.88, 73.68, 19.25;HRMS (ESI) calcd for C 15H 12ClN 6OS[M+H] +: 359.0482, found: 359.0486.
application examples 1the LSD1 of above-claimed cpd suppresses determination of activity:
1. experimental technique:
Sample is that above-claimed cpd, the purifying of embodiment synthesized obtains; Sample storing solution: take 3-5 mg sample and be placed in 1.5 mL EP pipes, be then mixed with DMSO the solution that concentration is 20 mM, 4 ° of C preserve and place, and dilute during experiment according to desired concn with DMSO.By testing sample and LSD1 albumen after incubated at room, add LSD1 reaction substrate H3K4me2 incubation reaction, finally add fluorescence dye Amplex and horseradish peroxidase HRP incubated at room, exciting light 530 nm in microplate reader, utilizing emitted light 590 nm detect fluorescence numerical value:
Test-results adopts SPSS computed in software IC 50value.
3. experimental result
Experimental result is shown in the following example 1shown in.
application examples 2above-claimed cpd is to tumour cell:
1. experimental technique:
Sample is that above-claimed cpd, the purifying of embodiment synthesized obtains; Sample storing solution: take 3-5 mg sample and be placed in 1.5 mL EP pipes, be then mixed with DMSO the solution that concentration is 10mM, 4 ° of C preserve and place, and utilize substratum dilution during experiment according to desired concn.
2. screening:
The cell of taking the logarithm vegetative period, after digestion counting, with substratum, adjust cell density, with 4000-8000 cell/ hole, be seeded in 96 orifice plates, every hole 100 μ L, cultivate after 24 h, discard substratum, add the medicine having diluted with substratum, each concentration is established 3 multiple holes, separately establishes blank group and positive controls.After drug effect 72 h, every hole adds 20 μ L MTT solution, continues to cultivate after 4 h, sucks liquid, adds the DMSO of 150 μ L, and evenly, absorbance is detected at microplate reader 490nm place in vibration, calculates inhibiting rate, and calculation formula is as follows:
Inhibiting rate (%)=(1-administration group absorbance/blank group absorbance) * 100%
Test-results adopts SPSS computed in software IC 50value and relation conefficient, result is as shown in table 2 below.
3. experimental result
Table 1 above-claimed cpd is to LSD1 and the inhibition activity data to LSD1:
The above-mentioned part preferred compound of table 2 is to gastric carcinoma cells (MGC-803, HGC-27, SGC-7901), liver cancer cell (HepG-2) and prostate cancer cell (PC-3) anti-tumor activity evaluating data:

Claims (5)

  1. Containing Urea,amino-with the pyrimidine derivatives of Terminal Acetylenes structural unit, it is characterized in that thering is structure described in general formula I,
    I
    R in general formula I 1for Cl, , , in any one;
    R 2for any one in following group:
    、 、 、 、 、 、 、 、 、 、 、 。
  2. 2. the Urea,amino-that contains as claimed in claim 1, with the pyrimidine derivatives of Terminal Acetylenes structural unit, is characterized in that: one of preferred following compound:
    R 1during for Cl: III-1 R 2=Phenyl;
    III-2 R 2=4-Chlorophenyl；
    III-3 R 2=3,4,5-Trimethoxylphenyl；
    III-4 R 2=3,4-Difluorophenyl；
    III-5 R 2=4-Bromophenyl；
    III-6 R 2=4-Isoproplphenyl；
    III-7 R 2=4-Fluorophenyl；
    III-8 R 2=4-Methylphenyl；
    III-9 R 2=4-Nitrophenyl；
    III-10 R 2=3-Chlorophenyl；
    III-11 R 2=2-Thienyl；
    R 1for time:
    I-1 R 2= Phenyl；
    I-2 R 2= 4-Chlorophenyl；
    I-3 R 2= 3,4,5-Trimethoxylphenyl；
    I-4 R 2= 3,4-Difluorophenyl；
    I-5 R 2= 4-Bromophenyl；
    I-6 R 2=4-Isoproplphenyl；
    I-7 R 2= 4-Fluoropheny；
    I-8 R 2=4-Methylphenyl；
    I-9R 2= 4-Nitrophenyl；
    I-10R 2=3-Chlorophenyl；
    I-11R 2=3-Methoxylphenyl；
    I-12 R 2=Thiophene；
    R 1for time:
    I-13 R 2= 3,4-Difluorophenyl；
    I-14 R 2=4-Methylphenyl；
    I-15 R 2=3-Chlorophenyl；
    I-16 R 2= 4-Nitrophenyl；
    I-17 R 2= 4-Bromophenyl；
    I-18 R 2=4-Chlorophenyl；
    I-19R 2=4-Isoproplphenyl；
    R 1for time:
    I-20 R 2= 4-Nitrophenyl。
  3. 3. prepare the method with the pyrimidine derivatives of Terminal Acetylenes structural unit containing Urea,amino-as described in claim 1 requirement, it is characterized in that: comprise following synthesis step:
    (1) preparation method of general formula I I:
    In solvent, ethyl cyanacetate is obtained to Compound I I with thiocarbamide, substituted benzoyl aldehyde reaction under alkaline condition; Alkali used is a kind of in sodium hydroxide, potassium hydroxide, sodium carbonate, salt of wormwood, sodium phosphate, ten phosphate dihydrate sodium, potassiumphosphate, saleratus, sodium bicarbonate, triethylamine; Solvent used is acetone, DMF, acetonitrile, ethanol, methyl alcohol, Virahol, 1, one of in 2-ethylene dichloride, methylene dichloride, chloroform, tetrahydrofuran (THF), dioxane, distilled water or wherein any two or three mixture; Reaction is carried out between 0-90 ℃;
    (2) preparation method of general formula III:
    In solvent, general formula I I reacts and obtains intermediate product with propargyl bromide, with thin-layer chromatography, monitors reaction process, until reacted; Without separation, directly in reaction system, drip phosphorus oxychloride, after having reacted, be poured in frozen water, stir, there is solid to separate out, suction filtration, obtains solid, obtains the solid of sterling compound III through column chromatography; Solvent used is acetone, DMF, acetonitrile, ethanol, methyl alcohol, Virahol, 1, one of in 2-ethylene dichloride, methylene dichloride, chloroform, tetrahydrofuran (THF), dioxane, distilled water or wherein any two or three mixture; Reaction is carried out between 0-90 ℃;
    (3) preparation method of target compound I:
    In solvent, compound corresponding in general formula III reacts with Urea,amino-compounds, and after question response completes, condensation, separates out solid, and suction filtration obtains corresponding compound in general formula I;
    Solvent used is acetone, DMF, acetonitrile, ethanol, methyl alcohol, Virahol, 1, one of in 2-ethylene dichloride, methylene dichloride, chloroform, tetrahydrofuran (THF), dioxane, distilled water or wherein any two or three mixture; Reaction is carried out between 0-90 ℃; Described Urea,amino-compounds is aminoguanidine, Urea,amino-or thiosemicarbazide;
    。
  4. 4. the application of the pyrimidine derivatives containing Urea,amino-and Terminal Acetylenes structural unit as claimed in claim 1 or 2 in medicine preparation, is characterized in that: using it as preparing based on the antitumor lead compound of target spot Methionin specificity demethylase.
  5. 5. the application of the pyrimidine derivatives containing Urea,amino-and Terminal Acetylenes structural unit as claimed in claim 4 in medicine preparation, is characterized in that: medicine or LSD1 inhibitor as activeconstituents for the preparation of anti-stomach cancer cell, liver cancer cell, prostate cancer cell.
CN201410295919.8A 2014-06-27 2014-06-27 Containing the pyrimidine derivatives of amino urea and Terminal Acetylenes structural unit, preparation method and application Active CN104119280B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201410295919.8A CN104119280B (en) 2014-06-27 2014-06-27 Containing the pyrimidine derivatives of amino urea and Terminal Acetylenes structural unit, preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201410295919.8A CN104119280B (en) 2014-06-27 2014-06-27 Containing the pyrimidine derivatives of amino urea and Terminal Acetylenes structural unit, preparation method and application

Publications (2)

Publication Number Publication Date
CN104119280A true CN104119280A (en) 2014-10-29
CN104119280B CN104119280B (en) 2016-03-16

Family

ID=51764946

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201410295919.8A Active CN104119280B (en) 2014-06-27 2014-06-27 Containing the pyrimidine derivatives of amino urea and Terminal Acetylenes structural unit, preparation method and application

Country Status (1)

Country Link
CN (1) CN104119280B (en)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2016198649A1 (en) 2015-06-12 2016-12-15 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
CN106432247A (en) * 2016-09-27 2017-02-22 郑州大学 Pyrimidotriazole compounds containing hydrazone bonds as well as preparation method and application of pyrimidotriazole compounds
CN106432248A (en) * 2016-09-27 2017-02-22 郑州大学 Pyrimidine and triazole containing LSD1 inhibitor and preparation method and application thereof
CN106478639A (en) * 2016-09-05 2017-03-08 郑州大学 The LSD1 inhibitor of pyrimido 1,2,4 triazole, its preparation method and application
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
CN107313082A (en) * 2017-07-25 2017-11-03 上海新阳半导体材料股份有限公司 Leveling agent, the metal plating compositions containing it, preparation method and application
CN107660205A (en) * 2015-04-03 2018-02-02 因赛特公司 Heterocyclic compound as LSD1 inhibitor
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
WO2019025588A1 (en) 2017-08-03 2019-02-07 Oryzon Genomics, S.A. Methods of treating behavior alterations
US10329255B2 (en) 2015-08-12 2019-06-25 Incyte Corporation Salts of an LSD1 inhibitor
CN110267945A (en) * 2016-03-01 2019-09-20 诺华股份有限公司 The benzazolyl compounds that cyano replaces and its purposes as LSD1 inhibitor
CN111187220A (en) * 2020-01-19 2020-05-22 郑州大学 Trifluoromethyl pyrimidine derivative containing Schiff base structural unit and preparation method and application thereof
WO2020188089A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
WO2020188090A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
WO2021004610A1 (en) 2019-07-05 2021-01-14 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2022214303A1 (en) 2021-04-08 2022-10-13 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067900A1 (en) * 1999-05-10 2000-11-16 Prometic Biosciences Ltd. Novel triazine-based detoxification agents and their use
CN103848815A (en) * 2014-03-13 2014-06-11 郑州大学 4-substituent-6-phenyl pyrimidine derivatives comprising carbamido fragments and preparation method and use of derivatives
CN103880822A (en) * 2014-04-02 2014-06-25 郑州大学 2,4,6-trisubstituted pyrimidine compounds containing 1,2,3-triazole, preparation method and application thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000067900A1 (en) * 1999-05-10 2000-11-16 Prometic Biosciences Ltd. Novel triazine-based detoxification agents and their use
CN103848815A (en) * 2014-03-13 2014-06-11 郑州大学 4-substituent-6-phenyl pyrimidine derivatives comprising carbamido fragments and preparation method and use of derivatives
CN103880822A (en) * 2014-04-02 2014-06-25 郑州大学 2,4,6-trisubstituted pyrimidine compounds containing 1,2,3-triazole, preparation method and application thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HEBA T. ABDEL-MOHSEN等: "Novel benzimidazole-pyrimidine conjugates as potent antitumor agents", 《EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY》 *
PENG-JU CHEN等: "Synthesis, in vitro antimicrobial and cytotoxic activities of novel pyrimidine-benzimidazol combinations", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 *

Cited By (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10717737B2 (en) 2014-02-13 2020-07-21 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10676457B2 (en) 2014-02-13 2020-06-09 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10174030B2 (en) 2014-02-13 2019-01-08 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9994546B2 (en) 2014-02-13 2018-06-12 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10513493B2 (en) 2014-02-13 2019-12-24 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US10300051B2 (en) 2014-02-13 2019-05-28 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US11247992B2 (en) 2014-02-13 2022-02-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9670210B2 (en) 2014-02-13 2017-06-06 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493450B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US11155532B2 (en) 2014-02-13 2021-10-26 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US10125133B2 (en) 2014-07-10 2018-11-13 Incyte Corporation Substituted [1,2,4]triazolo[1,5-a]pyridines and substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US10640503B2 (en) 2014-07-10 2020-05-05 Incyte Corporation Imidazopyridines and imidazopyrazines as LSD1 inhibitors
US10138249B2 (en) 2014-07-10 2018-11-27 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US10968221B2 (en) 2014-07-10 2021-04-06 Incyte Corporation Substituted [1,2,4]triazolo[1,5-a]pyrazines as LSD1 inhibitors
US10556908B2 (en) 2014-07-10 2020-02-11 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US10047086B2 (en) 2014-07-10 2018-08-14 Incyte Corporation Imidazopyridines and imidazopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
US10112950B2 (en) 2014-07-10 2018-10-30 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
US9944647B2 (en) 2015-04-03 2018-04-17 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
US10800779B2 (en) 2015-04-03 2020-10-13 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
CN107660205A (en) * 2015-04-03 2018-02-02 因赛特公司 Heterocyclic compound as LSD1 inhibitor
US11401272B2 (en) 2015-04-03 2022-08-02 Incyte Corporation Heterocyclic compounds as LSD1 inhibitors
WO2016198649A1 (en) 2015-06-12 2016-12-15 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
US10723700B2 (en) 2015-08-12 2020-07-28 Incyte Corporation Salts of an LSD1 inhibitor
US10329255B2 (en) 2015-08-12 2019-06-25 Incyte Corporation Salts of an LSD1 inhibitor
US11498900B2 (en) 2015-08-12 2022-11-15 Incyte Corporation Salts of an LSD1 inhibitor
CN110267945A (en) * 2016-03-01 2019-09-20 诺华股份有限公司 The benzazolyl compounds that cyano replaces and its purposes as LSD1 inhibitor
WO2017158136A1 (en) 2016-03-16 2017-09-21 Oryzon Genomics, S.A. Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10166221B2 (en) 2016-04-22 2019-01-01 Incyte Corporation Formulations of an LSD1 inhibitor
CN106478639A (en) * 2016-09-05 2017-03-08 郑州大学 The LSD1 inhibitor of pyrimido 1,2,4 triazole, its preparation method and application
CN106432247A (en) * 2016-09-27 2017-02-22 郑州大学 Pyrimidotriazole compounds containing hydrazone bonds as well as preparation method and application of pyrimidotriazole compounds
CN106432248A (en) * 2016-09-27 2017-02-22 郑州大学 Pyrimidine and triazole containing LSD1 inhibitor and preparation method and application thereof
WO2018083189A1 (en) 2016-11-03 2018-05-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
CN107313082B (en) * 2017-07-25 2018-08-17 上海新阳半导体材料股份有限公司 Leveling agent, the metal plating compositions containing it, preparation method and application
CN107313082A (en) * 2017-07-25 2017-11-03 上海新阳半导体材料股份有限公司 Leveling agent, the metal plating compositions containing it, preparation method and application
WO2019025588A1 (en) 2017-08-03 2019-02-07 Oryzon Genomics, S.A. Methods of treating behavior alterations
US11512064B2 (en) 2018-08-31 2022-11-29 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
WO2020188090A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating borderline personality disorder
WO2020188089A1 (en) 2019-03-20 2020-09-24 Oryzon Genomics, S.A. Methods of treating attention deficit hyperactivity disorder using kdm1a inhibitors such as the compound vafidemstat
WO2021004610A1 (en) 2019-07-05 2021-01-14 Oryzon Genomics, S.A. Biomarkers and methods for personalized treatment of small cell lung cancer using kdm1a inhibitors
CN111187220B (en) * 2020-01-19 2022-08-02 郑州大学 Trifluoromethyl pyrimidine derivative containing Schiff base structural unit and preparation method and application thereof
CN111187220A (en) * 2020-01-19 2020-05-22 郑州大学 Trifluoromethyl pyrimidine derivative containing Schiff base structural unit and preparation method and application thereof
WO2022214303A1 (en) 2021-04-08 2022-10-13 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors for treating myeloid cancers
WO2023217758A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating malignant peripheral nerve sheath tumor (mpnst) using lsd1 inhibitors
WO2023217784A1 (en) 2022-05-09 2023-11-16 Oryzon Genomics, S.A. Methods of treating nf1-mutant tumors using lsd1 inhibitors

Also Published As

Publication number Publication date
CN104119280B (en) 2016-03-16

Similar Documents

Publication Publication Date Title
CN104119280B (en) Containing the pyrimidine derivatives of amino urea and Terminal Acetylenes structural unit, preparation method and application
US9957259B2 (en) Selective HDAC1 and HDAC2 inhibitors
Sun et al. Discovery of a series of 1, 3, 4-oxadiazole-2 (3H)-thione derivatives containing piperazine skeleton as potential FAK inhibitors
ES2289349T3 (en) DERIVATIVES OF HETEROARIL-PYRIMIDINE AS JAK INHIBITORS.
CN1807413B (en) Carbazole sulfonamide derivative and its preparation method
EP3653620B9 (en) New heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and 2 (hdac1-2)
CN105646454B (en) The 2- aryl amine pyridine derivatives of the fragment containing hydroxamic acid and preparation and application
CN104356099B (en) Homoserine lactone compounds, its preparation method and application thereof
JP2009534450A (en) Novel imidazole derivatives, their preparation and their use as pharmaceuticals
CN105283443A (en) Heterocyclic derivatives and use thereof
WO2011161201A1 (en) Bisarylsulfonamides useful as kinase inhibitors in the treatment of inflammation and cancer
US8877946B2 (en) Benzylidene-indolinone compounds and their medical use
CN103880822A (en) 2,4,6-trisubstituted pyrimidine compounds containing 1,2,3-triazole, preparation method and application thereof
AU2012356738B2 (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
CN104119319B (en) Containing the pyrimidine derivatives and its production and use of 1,2,3-triazole and urea structure uint
CN111164087B (en) Compounds useful for inhibition of human trefoil factor 3
JP4604147B2 (en) Coumarin derivative
US10000449B2 (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
CN108864067B (en) 2-propargyl sulfydryl-5-cyanopyrimidine derivative and preparation method and application thereof
CN111454278B (en) PAK1 inhibitor, synthesis thereof and application thereof in preparation of antitumor drugs
KR100670171B1 (en) NOVEL FURO[2,3-d]PYRIMIDINE DERIVATIVES AS AKT1 KINASE INHIBITORS, INTERMEDIATES FOR PREPARING THE SAME, AND PREPARATION METHOD THEREOF
Eni et al. Design, synthesis, and biological and computational evaluation of novel oxindole derivatives as inhibitors of Aurora A Kinase and SARS-CoV-2 Spike/Host ACE2 Interaction
CN104761502A (en) Benzimidazole derivatives, and preparation method and pharmaceutical applications thereof
NZ626950B2 (en) Bisarylsulfonamides useful in the treatment of inflammation and cancer
CN103113365A (en) rhodanine quinazolinamine compound as well as preparation method and application thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant